|
BRAF mutations and clinical characteristics |
|||
| Clinical Features |
BRAF Status |
P value |
|
|
|
|||
| Mutation N = 30 (44.1%) |
Wild Type N = 38 (55.9%) |
||
|
|
|||
| Gender |
|||
| Female |
11 |
15 |
0.81 |
| Male |
19 |
23 |
|
| Age1 |
|||
| Mean |
63.3 |
57.3 |
0.12 |
| Median (range) |
56.5 (29–91) |
65.0 (42–97) |
|
| Stage at Diagnosis |
|||
| I |
5 |
3 |
0.92 |
| II |
13 |
19 |
|
| III |
7 |
10 |
|
| IV |
4 |
2 |
|
| Unknown |
1 |
4 |
|
| Thickness (Number available) |
(N = 18) |
(N = 22) |
|
| Mean |
2.98 |
4.83 |
0.29 |
| Median (range) |
1.75 (0.2, 20) |
2.80 (0.4, 35) |
|
| Primary Site |
|||
| Head/Neck |
1 |
6 |
|
| Trunk |
10 |
11 |
|
| Extremities |
10 |
14 |
|
| Ocular |
1 |
0 |
|
| Mucosal |
1 |
0 |
|
| Unknown |
7 |
7 |
|
| Response2 |
|||
| CR |
2 |
3 |
|
| PR |
0 |
2 |
|
| NR |
16 |
10 |
|
| Response Rate |
11% |
33% |
0.12 |
|
1 Age at time of biopsy used to assess BRAF sequence. 2 Response data is based on the 33 patients who received systemic therapy. | |||
Chang et al. Journal of Translational Medicine 2004 2:46 doi:10.1186/1479-5876-2-46 |
|||